J&J "Dear Healthcare Provider" Letter On Risperdal Leads To $257.7 Million Jury Award
This article was originally published in The Pink Sheet Daily
Executive SummaryA jury finds that J&J misrepresented the safety profile of Risperdal in a verdict for the state of Louisiana; each letter and sales rep call was counted as a separate violation.
You may also be interested in...
In the midst of a trial, Johnson & Johnson agrees to pay $158 million to settle a suit by the state of Texas alleging the company promoted Risperdal off-label to children. Two states previously won jury verdicts over the company’s marketing of the antipsychotic.